Will tiny OncoSec break out with promising melanoma immunotherapy study results? – STAT
STAT |
Will tiny OncoSec break out with promising melanoma immunotherapy study results?
STAT he addition of an experimental immunotherapy from OncoSec Medical (ONCS 1) to Merck's (MRK 2) checkpoint inhibitor Keytruda is shrinking tumors in almost half of the skin cancer patients treated in a small clinical trial, according to updated results … OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in … |
